First Hemoadsorption during Cardiopulmonary Bypass in Neonate with Complex Cardiac Malformation

Emeline Christophel-Plathier1*, Vitor Mendes2, Francois Verdy2, Sylvain Mauron1 and Caroline Mury1

1Department Anesthesiology, Lausanne University Hospital (CHUV), Switzerland
2Department Cardiac Surgery, Lausanne University Hospital (CHUV), Switzerland

^*Correspondance to: Emeline Christophel-Plathier 

 PDF  Full Text Case Report | Open Access

Abstract:

Cardiac surgery with Cardiopulmonary Bypass (CPB) is a trigger of significant Systemic Inflammatory Response Syndrome (SIRS) with an accompanying cytokine release. Additional factors increasing the risk of post-operative SIRS include surgery itself, long CPB duration, and mechanical hemolysis and ischemia-reperfusion injuries. Cytosorb® is a hemoadsorption device that removes many cytokines from the blood. Pediatric patients with exaggerated pre-operative SIRS might be good candidates for an assessment of Cytosorb’s® usefulness. We present the case of a fullterm newborn with a hypoplastic left heart syndrome. Five days after birth, the patient underwent a Norwood stage I palliation under CPB with adjunction of Cytosorb®. Post-operative course was uneventful, hemodynamic adaptation was good, with rapid weaning off all amine infusions.

Keywords:

Cite the Article:

Christophel-Plathier E, Mendes V, Verdy F, Mauron S, Mury C. First Hemoadsorption during Cardiopulmonary Bypass in Neonate with Complex Cardiac Malformation. Ann Clin Case Rep. 2022; 7: 2257.